Anti-TNFAIP8L3 Antibody

Western Blot analysis of 1, 293T 2, mouse-brain cells using primary antibody diluted at 1:1000 (4°C overnight). Secondary antibody:Goat Anti-rabbit IgG IRDye 800 ( diluted at 1:5000, 25°C, 1 hour)

T1: The expression and clinical significance of TIPE3 in PC. A Representative IHC staining of TIPE3. B IHC sum scores were applied to assess TIPE3 in PC specimens. C ) IHC staining of TIPE3 in PC tissues with or without lymph node metastasis. D IHC sum scores were applied to assess TIPE3 in PC specimens with or without lymph node metastasis. E TIPE3 expression in negative lymph node and metastatic lymph node. F Survival analysis according to TIPE3 expression in 188 PC patients. G Prognostic Nomogram of 188 PC patients. H Calibration curves of the OS nomogram. (I-K) DCA for the OS nomogram at 1-year I 2-year J and 3-year K . ***, P < 0.001. T2. The clinical significance of TIPE3 A IHC sum scores were applied to determine TIPE3 in PC. B IHC sum scores were applied to assess TIPE3 expression in PC specimens. C Survival analysis using TIPE3 in 66 PC patients. *, P < 0.05; ***, P < 0.001. T3. TIPE3 promoted malignant biological behaviors of PC cells. A Detection of TIPE3 mRNA expression using qRT-PCR. B TIPE3 expression were detected after TIPE3 silencing or overexpression using qRT-PCR. C CCK8 analysis was conducted after TIPE3 silencing in AsPC-1 and PANC-1 cells. D CCK8 analysis was conducted after TIPE3 overexpression in PC cells. E Trans-well assays were performed after TIPE3 silencing or overexpression in AsPC-1 cells. F Trans-well assays were performed after TIPE3 silencing or overexpression in PANC-1 cells. *, P < 0.05; **, P < 0.01; ***, P < 0.001. T4. TIPE3 promoted tumor progression and metastasis in mice. A Tumor growth curve of orthotopic xenograft mouse. B Representative pictures of primary tumors in pancreas. B Tumor volume in NC, shTIPE3 and TIPE3 group, respectively. D Tumor weight in NC, shTIPE3 and TIPE3 group, respectively. E Survival curves of different groups. F The representative of bioluminescent images in metastatic mouse model. G Number of liver metastatic foci were recorded. H Number of peritoneal metastatic tumors were recorded. *, P < 0.05; **, P < 0.01; ***, P < 0.001
Index in PubMed under a CC BY license. PMID: 35941647

T1: TIPE3 increased RAC1 in PC. A IHC staining of RAC1. B IHC sum scores were applied to determine RAC1 expression. C IHC sum scores of RAC1 in PC tissues with low or high TIPE3 expression. D Western-blot was conducted to detected RAC1 expression after TIPE3 silencing or overexpression. E Quantified results of western-blot for RAC1 expression in PC cells. F IHC staining of TIPE3, RAC1, RhoA and MMP9 in orthotopic xenograft tumors. G IHC sum scores of TIPE3, RAC1, RhoA and MMP9 expression in orthotopic xenograft tumors. *, P < 0.05; **, P < 0.01; ***, P < 0.001. T2. TIPE3 accelerated the malignant behaviors of PC cells in a RAC1-dependent manner. A NSC23766 (50 μM) was used in CCK8 analysis. B CCK8 assays was measurement after RAC1 silencing in PC cells. C Trans-well assays after treatment of NSC23766 (50 μM). D Trans-well assays were measurement after RAC1 silencing in PC cells. E CCK8 assays were measurement in TIPE3 silencing PC cells that pretreated with NSC23766 (50 μM) or transfection with RAC1 siRNA. F CCK8 assays were conducted in TIPE3 overexpressed PC cells that pretreated with NSC23766 (50 μM) or transfection with RAC1 siRNA. G Trans-well assays were conducted in TIPE3 silenced PC cells that pretreated with NSC23766 (50 μM). H Trans-well assays were conducted in TIPE3 silenced PC cells that transfected with RAC1 siRNA. I Trans-well assays were conducted in TIPE3 overexpressed PC cells that pretreated with NSC23766 (50 μM). J Trans-well migration and invasion assays were conducted in TIPE3 overexpressed PC cells that transfected with RAC1 siRNA
Index in PubMed under a CC BY license. PMID: 35941647